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Background: Venous malformation (VM) is the most common form of vascular malfor-
mation, consisting of a network of thin-walled ectatic venous channels with deficient or 
absent media. This study investigated the expression of the components of the renin–
angiotensin system (RAS), namely, (pro)renin receptor (PRR), angiotensin-converting 
enzyme (ACE), angiotensin II receptor 1 (ATIIR1), and angiotensin II receptor 2 (AIITR2) in 
subcutaneous (SC) and intramuscular (IM) VM.
Materials and methods: SC (n = 7) and IM (n = 7) VM were analyzed for the expression 
of PRR, ACE, ATIIR1, and ATIIR2 using 3,3-diaminobenzidine and immunofluorescent 
(IF) immunohistochemical (IHC) staining and NanoString gene expression analysis.
results: IHC staining showed expression of PRR, ACE, and ATIIR1, and faint expression 
of ATIIR2 in the endothelium of SC and IM VM. Furthermore, ATIIR2 was expressed by 
cells away from the endothelium in both SC and IM VM lesions examined. NanoString 
analysis demonstrated the presence of PRR, ACE, and ATIIR1 but not ATIIR2.
conclusion: The presence of PRR, ACE, ATIIR1, and potentially ATIIR2, in both SC and 
IM VM, suggests a role for the RAS in the biology of VM. This novel finding may lead to 
a mechanism-based therapy for VM.
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inTrODUcTiOn
Vascular anomalies are classified by the International Society for the Study of Vascular Anomalies 
classification system into vascular tumors and vascular malformations (1). Infantile hemangioma 
(IH) is the most common type of vascular tumor (1). Vascular malformation affects arteries, veins, 
lymphatics, and capillaries singly or in combinations, with venous malformation (VM) being the 
most common (1).
Venous malformation affects 1.5% of the population (2) and is characterized by thin-walled 
ectatic venous channels lined by flat endothelial cells (EC) with deficient or absent smooth muscle 
cells (SMC) (3, 4). VM may involve any body site and tissue (4), commonly in subcutaneous (SC) 
and less commonly in intramuscular (IM) locations (5). Although VM is present at birth, it may not 
become apparent until later in life (3–5). Its clinical presentation depends on the location and size of 
the lesion. SC lesions typically present as compressible masses with a bluish hue, whereas IM lesions 
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often present with a swelling and/or pain (4). VM may cause 
cosmetic concerns and/or functional deficits, such as obstructive 
sleep apnea as in the case of oropharyngeal lesions (6). VM grows 
proportionately with the growth of the child and may suddenly 
expand in response to hormonal changes or trauma, including 
incomplete surgical excision (3–5).
About 1–2% of VM cases are familial caused by a TIE2 muta-
tion (7). Half of the sporadic cases also consists a TIE2 somatic 
mutation (7). These mutations have been shown to result in 
ligand-independent hyper-phosphorylation of the TIE2 receptor 
(7). Vikkula et al. (8) suggest that the TIE2 mutation in EC in VM 
may reduce SMC ligand expression causing a local uncoupling 
between normal SMC recruitment and the proliferation of EC.
Furthermore, more recent demonstration of hormone recep-
tor proteins, such as follicle-stimulating hormone receptor (9) 
and the growth hormone receptor (10) within VM, highlights 
other potential pathways that may play a critical role in the biol-
ogy of VM.
The classical renin–angiotensin system (RAS) consists of the 
enzyme renin, which converts angiotensinogen to angiotensin I 
(ATI) (11). ATI is subsequently cleaved by angiotensin-converting 
enzyme (ACE), also known as CD143, to form angiotensin II 
(ATII) (11). The vasoactive peptide ATII then acts on angiotensin 
II receptor 1 (ATIIR1) and angiotensin II receptor 2 (ATIIR2) 
(11).
Previous work has identified the presence of primitive meso-
dermal cells with a neural crest phenotype in IH (12), regulated 
by the RAS (13). These discoveries of the stem cell nature of IH, 
regulated by the RAS, underscore the natural involution and 
accelerated involution of this tumor, induced by β-blockers and 
ACE inhibitors (14–16).
This study aimed to identify the expression of the components 
of the RAS, namely, PRR, ACE, ATIIR1, and ATIIR2, in both SC 
and IM VM.
MaTerials anD MeThODs
Tissues
Subcutaneous VM tissues from seven patients aged 9–30 years 
(mean, 22.2  years) and IM VM from seven patients aged 
16 months–54 years (mean, 21.3 years) were sourced from the 
Gillies McIndoe Research Institute Tissue Bank, in accordance 
with a protocol approved by the Central Health and Disability 
Ethics Committee (ref. no. 13/CEN/130). The tissues used in 
this study were confirmed to be SC or IM VM by a consultant 
anatomical pathologist (HDB) using hematoxylin and eosin 
(H&E) staining and D2-40 staining to exclude lymphatic 
malformation.
immunohistochemical staining
3,3-Diaminobenzidine (DAB) and immunofluorescent (IF) 
immunohistochemical (IHC) staining were performed on 
4-μm-thick formalin-fixed paraffin-embedded sections of VM 
samples as reported previously (17). In brief, IHC staining 
was undertaken using the Leica Bond Rx auto-stainer (Leica, 
Nussloch, Germany) with antibodies against CD34 (ready-to-use; 
cat#PA0212, Leica), ERG (1:200; cat#EP111, Cell Marque, Santa 
Cruz, CA, USA), SMA (ready-to-use; cat#PA0943, Leica), D2-40 
(1:100; cat#M3619, Dako, Glostrup Denmark), PRR (1:100; 
cat#HPA003156, Sigma), ACE (1:40; cat#3C5, Serotec, Raleigh, 
NC, USA), ATIIR1 (1:25; cat#ab9391, Abcam, Cambridge, MA, 
USA), and ATIIR2 (1:2000; cat#NBPI-77368, Novus Biologicals, 
Littleton, CO, USA). All antibodies were diluted in Bond primary 
diluent (Leica). For IF IHC detection, a combination of Vectafluor 
Excel anti-rabbit 594 (ready-to-use; cat#VEDK-1594, Vector 
Laboratories, Burlingame, CA, USA) and Alexa Fluor anti-mouse 
488 (1:500; cat#A21202, Life Technologies, San Diego, CA, USA) 
were used to detect combinations that included PRR and ATIIR2, 
and Vectafluor Excel anti-mouse (ready-to-use; cat#VEDK2488, 
Vector Laboratories) and Alexa Fluor anti-rabbit 594 (1:500; 
cat#A21207, Life Technologies) to detect combinations that 
included ACE and ATIIR1.
All DAB IHC-stained slides were mounted in Surgipath 
Micromount (cat#3801732, Leica). All IF IHC-stained slides were 
mounted in Vectashield HardSet antifade mounting medium 
with DAPI (cat#H-1500, Vector Laboratories).
Positive control samples were selected based on the previously 
reported expression of the relevant proteins: placenta for PRR 
(18), kidney for ACE (19) and ATIIR2 (20), and liver for ATIIR1 
(20). To determine the specificity of the primary antibodies, 
staining of VM sections was performed by omitting the primary 
antibodies.
image analysis
All DAB and IF IHC-stained slides were viewed and imaged using 
the Olympus BX53 microscope fitted with an Olympus DP21 
digital camera (Olympus, Tokyo, Japan) and an Olympus FV1200 
biological confocal laser-scanning microscope (Olympus, Tokyo, 
Japan), respectively. IF IHC images were processed with cellSens 
Dimension 1.11 software using 2D deconvolution algorithm 
(Olympus).
nanostring gene expression analysis
Total RNA was extracted from ~10 mg of snap-frozen IM (n = 3) 
and SC (n =  3) VM tissues from the same cohorts of patients 
included in DAB IHC staining, using RNeasy Mini Kit (Qiagen, 
Hilden, Germany) and quantitated with the NanoDrop 2000 
Spectrophotometer (Thermo Scientific). The samples with A260/
A230 ≥1.8 and A260/A280 ≥1.9 were used for further analysis. 
The integrity of the RNA was assessed by Agilent 2100 BioAnalyser 
(Agilent Technologies, Santa Clara, CA, USA). The isolated RNA 
was then subjected to NanoString nCounter™ Gene Expression 
Assay (NanoString Technologies, Seattle, WA, USA) and com-
pleted by New Zealand Genomics, Ltd. (Dunedin, New Zealand), 
according to the manufacturer’s protocol. Probes for the genes 
encoding PRR (ATP6AP2, NM_005765.2), ACE (NM_000789.2), 
ATIIR1 (NM_000685.3), ATIIR2 (NM_000686.3), and the 
housekeeping gene, GAPDH (NM_002046.3) were designed and 
synthesized by NanoString Technologies.
FigUre 1 | representative h&e stained slides of iM (a) and sc (B) VM showing thin-walled ectatic lesional vessels with variable density of  
smooth muscle cells. Original magnification: 100×.
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statistical analyses
Raw NanoString data were analyzed using SPSS (v22, IBM), cor-
roborated with nSolver™ software (NanoString Technologies) 
using standard settings, and normalized against the housekeep-
ing gene. To determine the level of confidence between the IM 
and SC VM samples, two-tailed Student’s t-test was performed. 
Charts were made with Excel (Microsoft Office 2013).
resUlTs
histochemical and DaB 
immunohistochemical staining
The vasculature within the VM lesions was identified by H&E 
staining, characterized by thin-walled ectatic venous channels 
with deficient or absent SMC in both IM (Figure  1A) and SC 
(Figure  1B) VM. None of the IM or SC VM lesions used in 
this study expressed D2-40 (Figures S1A,B in Supplementary 
Material, brown).
PRR was expressed on the endothelium of both IM (Figure 2A, 
brown) and SC (Figure 2B, brown) VM. ACE, which converts 
ATI to ATII, was expressed on the endothelium of IM (Figure 2C, 
brown) and SC (Figure 2D, brown) VM. To demonstrate a poten-
tial receptor available for downstream signaling of ATII, staining 
for ATIIR1 and ATIIR2 was performed. This demonstrated the 
expression of ATIIR1 on the endothelium of IM (Figure  2E, 
brown) and SC (Figure 2F, brown) VM. There was faint staining 
of ATIIR2 of the endothelium and cells away from the endothe-
lium of both IM (Figure 2G, brown) and SC (Figure 2H, brown) 
VM lesions studied.
There was relatively more intense staining for ATIIR1, in both 
IM and SC VM, in the smaller lesional vessels (Figures  3A,B, 
brown, thin arrow) compared to the dilated vessels (Figures 3A,B, 
brown, thick arrow).
Positive controls for PRR (Figure S2A in Supplementary 
Material, brown), ACE (Figure S2B in Supplementary Material, 
brown), ATIIR1 (Figure S2C in Supplementary Material, brown), 
ATIIR2 (Figure S2D in Supplementary Material, brown), and 
negative control with omission of the primary antibodies (Figure 
S2E in Supplementary Material, brown) demonstrated appropri-
ate specificity for the antibodies used.
immunoflourescent immunohistochemical 
staining
The endothelium of all IM (Figures  4A,C,E,G) and SC 
(Figures  4B,D,F,H) VM were identified by either CD34 
(Figures 4A,B,G,H, green) or ERG (Figures 4C–F, red). IF IHC 
staining demonstrated the expression of PRR on the endothe-
lium of IM (Figure 4A, red) and SC (Figure 4B, red) VM. The 
expression of ACE was demonstrated on the endothelium of IM 
(Figure 4C, green) and SC (Figure 4D, green) VM. ATIIR1 was 
expressed on the endothelium of IM (Figure 4E, green) and SC 
(Figure 4F, green) VM. ATIIR2 was also demonstrated on cells 
of the endothelium as well as cells away from the endothelium 
in both IM (Figure 4G, red) and SC (Figure 4H, red) VM. Cell 
nuclei were highlighted in blue (Figures  4A–H). Individual IF 
IHC staining for each of the aforementioned proteins is shown in 
Figure S3 in Supplementary Material.
Negative controls for IF IHC staining demonstrated appropri-
ate specificity of the primary antibodies in anti-mouse (Figure 
S4A in Supplementary Material, green) and anti-rabbit (Figure 
S4B in Supplementary Material, red) combinations.
nanostring gene analysis
NanoString gene analysis showed that mRNA corresponding 
to PRR, ACE, and ATIIR1, but not ATIIR2, was detected in IM 
(Figure 5A) and SC (Figure 5B) VM tissue samples. The following 
average counts were calculated as expression relative to GAPDH, 
with their respective SEM for IM VM, PRR 0.00844 ± 0.0050, 
ACE 0.00064  ±  0.0002, and ATIIR1 0.00271  ±  0.0057; SC 
VM PRR 0.0809 ± 0.0238, ACE 0.0502 ± 0.0473, and ATIIR1 
0.0191 ± 0.0087. Expression of PRR was higher in SC than IM 
samples, and this was statistically significant (p < 0.05).
DiscUssiOn
This report provides novel findings of the presence of PRR, ACE, 
ATIIR1, and potentially ATIIR2 within both IM and SC VM.
The demonstration of PRR on the endothelium of VM high-
lights the putative role of this receptor in the biology of VM, 
including binding pro-renin and renin and downstream signaling 
FigUre 3 | aTiir1 was expressed to a greater degree in the smaller lesional vessels [(a,B), brown, thin arrow], compared with the adjacent dilated 
lesional vessels [(a,B), brown, thick arrow] in both iM (a) and sc (B) VM. Original magnification: 400×.
FigUre 2 | representative DaB ihc-stained sections of iM [(a,c,e,g), brown] and sc [(B,D,F,g), brown] VM demonstrating the expression of Prr in iM 
[(a), brown] and sc [(B), brown] lesions. ACE was also expressed on the endothelium of IM [(c), brown] and SC [(D), brown] lesions. ATIIR1 was expressed in both 
IM [(e), brown] and SC [(F), brown] lesions. Faint staining of ATIIR2 was seen on the endothelium of IM [(g), brown] and SC [(h), brown] VM. Original magnification: 400×.
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FigUre 4 | representative iF ihc-stained sections of iM (a,c,e,g) and sc (B,D,F,h) VM demonstrating the expression of Prr in iM [(a), red] and  
sc [(B), red] lesions. Endothelial cells were identified by the endothelial marker CD34 [(a,B), green]. ACE was also expressed on the endothelium of IM [(c), green] 
and SC [(D), green] lesions. ATIIR1 was expressed on the endothelium of both IM [(e), green] and SC [(F), green] VM. The endothelial cells were identified using the 
endothelial marker ERG [(c–F), red]. ATIIR2 also demonstrated positive staining in IM [(g), red] and SC [(h), red] VM. The endothelial cells were identified using 
CD34 [(g,h), green]. Cell nuclei were counterstained with 4′,6-diamidino-2-phenylindole (blue). Scale bars: 20 μm.
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FigUre 5 | Prr, ace, and aTiir1 mrna levels in sc (n = 3) (a) and iM (n = 3) (B) VM tissues. Total mRNA was analyzed by NanoString nCounter Gene 
Expression assay with specific probes for PRR, ACE, ATIIR1 and ATIIR2 genes. Counts from ATIIR2 did not exceed those of the negative control.
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through MAP kinases ERK1 and ERK2 (18). Pro-renin bound 
to PRR undergoes a conformational change, exposing the active 
sites and rendering it enzymatically active (11). Renin bound to 
PRR leads to a fourfold increase in catalytic activity (18). The 
presence of PRR on the endothelium of VM indicates a potential 
role for facilitating increased local conversion of angiotensinogen 
to ATI, indicating a role for this peptide in VM biology.
ACE has been reported as a marker for identifying primitive 
hemangioblasts derived from human pluripotent stem cells (21). 
It is exciting to speculate that the endothelium of VM, which we 
have demonstrated to express this marker, may reflect a relative 
primitive phenotype for this endothelium; however, this is the 
topic of our current investigation.
It is intriguing that both DAB and IF IHC analysis revealed 
positive staining for ATIIR2 on the endothelium as well as 
cells away from the endothelium, but that its expression was 
not demonstrated by NanoString gene expression analysis. The 
reasons for these include possible non-specific binding of the 
primary antibody used for IHC staining, despite appropriate 
controls being used, or that the probe used for the NanoString 
analysis failed to cover all the possible mRNA splice variants for 
this protein. Furthermore, it is interesting to note that the DAB 
IHC analysis of the SC and IM VM samples revealed relatively 
increased staining for ATIIR1 on the endothelium of smaller 
vessels compared to the dilated vessels, the reasons for which 
extend beyond this study.
The presence of PRR, ACE, ATIIR1, and potentially ATIIR2 
in VM  indicates a potential role for the RAS in this condition. 
Nguyen Dinh Cat et al. (22) have demonstrated the components 
of the RAS including PRR, ACE, ATIIR1, and ATIIR2 in normal 
vascular tissues. ATIIR1 and ATIIR2 have been shown to serve 
distinct functions, but share ATII as a common ligand (20). 
The demonstration of ATIIR1, and potentially ATIIR2, in VM 
presented here does not delve into the functional roles of these 
proteins in VM, as this is the topic of further study. However, 
given ATIIR1 is responsible for the proangiogenic effects of 
ATII (23), this may, in part, explain the increased density of 
abnormal venous channels within VM. The presence of ATIIR2 
may indicate cellular differentiation determination, as previously 
proposed by Zambidis et al. (21).
A recent case report observing reduction of rectal bleeding 
and anemia from a VM affecting the rectosigmoid junction 
following administration of propranolol and celecoxib (24) 
was attributed by the authors to the vasoconstrictive effect of 
propranolol, a β-blocker, and the inhibitory effect of celecoxib, a 
COX-2 inhibitor, on vascular endothelial growth factor (VEGF) 
(24). The serendipitous observed clinical response in this case 
could potentially be explained by the inhibitory effects of the 
β-blocker and COX-2 inhibitor on the RAS. Our study demon-
strates the expression of PRR on the endothelium of VM, and 
we hypothesize that the observed effect of these medications 
is via the reduction in plasma renin levels by a β-blocker (25) 
and mitigation of ATII-induced expression of PRR by a COX-2 
inhibitor (26).
The putative primitive endothelial phenotype in VM is partially 
supported by the demonstration of positive cytoplasmic staining 
for stem cell growth factor receptor, c-kit, in small lesional vessels, 
but not in dilated vessels, of VM (27). We have reported a similar 
pattern of stronger staining for ATIIR1 on the endothelium of 
smaller lesional vessels, and it is exciting to speculate that the 
absence of c-kit in dilated lesional vessels may indicate that the 
latter are more mature and can no longer maintain a putative stem 
Ang-2
VEGF
Ang-1
ATII
? MAPK
PKC
ATIIR1
TIE2
FigUre 6 | schematic representation of a proposed mechanism 
through which aTii leads to over-activation of Tie2 (see text). Ligands 
(yellow), receptors (orange), and intracellular signaling (white). Abbreviations: 
ATII, angiotensin II; ATIIR1, angiotensin II receptor 1; PKC, protein kinase C; 
MAPK, mitogen-activated protein kinase; Ang-1, angiopoetin-1; Ang-2, 
angiopoetin-2; VEGF, vascular endothelial growth factor.
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cell population, with the smaller vessels as potential precursors. 
However, this is a topic of our ongoing research. This observa-
tion would therefore suggest that the smaller lesional vessels are 
the precursors of the more mature and ectatic vessels, but this is 
beyond the scope of this study.
TIE2 gene mutations have been implicated in VM (7), although 
the exact mechanism leading to the development of VM has yet 
to be fully elucidated. Vikkula et al. (8) propose a role in coupling 
of EC proliferation and SMC recruitment.
A previous study shows that ATII, acting through ATIIR1, 
stimulates the production of angiopoietin-2 (Ang-2), a ligand 
for TIE2 (28). Given that Ang-2 modulates the effect of angi-
opoietin-1 (Ang-1) on TIE2 (29) as well as increases the effects 
of VEGF. Based on our findings, it is exciting to speculate that 
increased signaling via ATIIR1 results in increased produc-
tion of Ang-2, ultimately leading to the development of VM, 
via activation of TIE2 (8, 29). Figure 6 shows our proposed 
model for the pathogenesis of VM incorporating a role for 
the RAS.
Current treatments of VM aim to relieve symptoms caused 
by VM, but they often neither halt nor reverse the underlying 
process that leads to the development and expansion of these 
lesions, limiting their efficacy (30), and depending on the location 
of the lesion, may not be feasible.
To the best of our knowledge, this is the first report dem-
onstrating the presence of PRR, ACE, ATIIR1, and potentially 
ATIIR2 in IM and SC VM. This novel finding suggests the 
RAS as a potential therapeutic target for VM using RAS 
modulators.
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FigUre s1 | representative DaB ihc-stained sections of iM (a) and  
sc (B) VM stained for D2-40 (brown) demonstrating no immunoreactivity 
except for normal lymphatic vessels in the periphery. Original  
magnification: 100×.
FigUre s2 | Positive controls for DaB ihc staining: placenta for  
Prr [(a), brown], kidney for ace [(B), brown], liver for aTiir1 [(c), 
brown], and kidney for aTiir2 [(D), brown] and a section of VM as a 
negative control by omitting the primary antibody [(e), brown]. Original 
magnification: 400×.
FigUre s3 | images of iF ihc-stained sections of iM (a,c,e,g,i,K,M,O) 
and sc (B,D,F,h,J,l,n,P) VM, showing expression of Prr [(a,B), red], 
ace [(e,F), green], aTiir1 [(i,J), green], and aTiir2 [(M,n), red]. Endothelial 
cells were marked by either CD34 [(C,D,O,P), green] or ERG [(G,H,K,L), red] 
staining. Cell nuclei were counterstained with 4′,6-diamidino-2-phenylindole 
(blue). Scale bars: 20 μm.
FigUre s4 | negative controls for iF ihc staining, demonstrating 
appropriate specificity of primary antibodies in anti-mouse [(a), green] 
and anti-rabbit [(B), red] combinations. Scale bars: 20 μm.
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